

1/14

Fig. 2






Fig. 3a:



BALB/c mice immunized with



BALB/c mice immunized with


Fig. 4:

mouse sera tested against hemagglutinin derived from strain:

 \boxtimes

A/New Caledonia/20/99 (H1/N1)

A/Panama/2007/99 (H3/N2)



BALB/c mice immunized with

C57BL/6 mice vaccinated with ' peptide + KLK/o-d(IC)13




Fig. 5a:

IFNg ELIspot

Fig. 5b:

% survival of challenged C57BL/6 mice

WO 2004/084938








Fig. 6:








10/14



BALB/c mice immunized with

Fig. 8b:



BALB/c mice immunized (i.m.) with

naive

9μg Agrippal S1

12/14


Fig. 9a: restimulation with: Medium OVA [10µg/ml] Agrippal S1 [1µg/ml] 200 No. of IFN-y producing cells/ million splenocytes IFN-γ 100 THE PARTY OF THE P 0 IL-4 No. of IL-4 producing cells/ million splenocytes 250 200 150 100 50 0 9µg Agrippa13 ! No. of IL-5 producing cells/ IL-5 200 100


BALB/c mice immunized with

1μg Agrippal S1

1µg Agrippal S1 10nmol KLK 0.4nmol ODN1a 1μg Agrippal S1 5nmol KLK 0.2nmol ODN1a 1μg Agrippal S1 1nmol KLK 0.04nmol ODN1a

Fig. 9b:





BALB/c mice immunized with

